New Research on Anatabine's Beneficial Effect on Alzheimer's Disease Presented at Neuroscience 2012

Oct 17, 2012, 10:00 ET from Star Scientific, Inc.

GLEN ALLEN, Va., Oct. 17, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., reports that scientists from its research partner, the Roskamp Institute, presented research this week showing that anatabine supplementation reduces the pathology and signs in an animal model of Alzheimer's disease.  The findings were presented in New Orleans, Louisiana, at Neuroscience 2012, the 42nd annual meeting of the Society for Neuroscience, as part of a series of presentations by researchers from the Roskamp Institute on supplementation with anatabine, the active ingredient in the Company's Anatabloc® dietary supplement. Neuroscience 2012 is the world's largest and most prestigious scientific meeting dedicated to brain and neurological science, with more than 32,000 neuroscientists from around the world gathering to observe and participate in presentations relating to more than 16,000 new discoveries in science and health.

(Logo: )

Megha Verma of the Roskamp Institute delivered the poster presentation titled, "Anti-Inflammatory and Amyloid Beta Lowering Properties of Anatabine in a Transgenic Mouse Model of Alzheimer's Disease", in which scientists reported that anatabine treated Alzheimer's mice retained their memory and learning compared to the untreated Alzheimer's mice.  Dr. Michael Mullan, President and CEO of the Roskamp Institute, stated, "In examining how anatabine works, the researchers show that key molecules which govern inflammation were deactivated, and this is important because we know that inflammation both promotes and maintains the deterioration of the brain in Alzheimer's disease."  

Last year, the Company reported the publication of the first peer-reviewed article on the in-vitro and in-vivo activity of anatabine in Alzheimer's Disease in the European Journal of Pharmacology (Paris et al. 2011 Sept 19). This week's presentation in New Orleans expands upon that published work and marks the first time the data have been presented at an international scientific convention.

In addition to the research on Alzheimer's disease, earlier in the conference, the Roskamp Institute presented results of research examining the potential benefit of anatabine for alleviating symptoms associated with multiple sclerosis and in helping with recovery from traumatic brain injury.  (To view the Company's press releases on these presentations, click here:

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical and low-TSNA tobacco products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our nutraceutical and low-TSNA tobacco products, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

About Star Scientific Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism, as well as to reduce the harm associated with the use of tobacco at every level. Over the last several years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, and the development of other nutraceuticals and pharmaceuticals. The company also has continued to pursue the development, implementation, and licensing of the technology behind its proprietary StarCured® tobacco curing process, which substantially prevents the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines, or TSNAs and related low-TSNA dissolvable tobacco products. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA; Executive, Scientific & Regulatory Affairs offices in Bethesda, MD, and Washington, DC; and a manufacturing facility in Chase City, VA.

 Talhia T. Tuck 
 Vice President, Communications and Investor Relations 
 Star Scientific, Inc.  


SOURCE Star Scientific, Inc.